Syneron Bio closed a $150 million Series B to support its macrocyclic peptide development platform, following a multibillion-dollar AstraZeneca biobucks deal and nearly $100 million raised last year. The funding reinforces Syneron’s focus on discovery-to-clinic execution for macrocyclic peptides, a chemistry platform where potency and stability are often key differentiators. For biotech investors and partners, the timing is notable: peptide platform funding is typically linked to near-term IND/clinical translation milestones. Syneron’s ability to raise at this scale also points to ongoing confidence in macrocyclic peptide modalities. The company’s disclosed purpose for the round—platform investment for therapeutic pipeline build—signals continued expansion rather than purely milestone-driven financing.